Omada Health, which just nabbed $48 million in new funding, expects to have "hundreds of thousands" of health plan enrollees using its digital health services by next year, CEO Sean Duffy says.
The San Francisco-based startup helps people with obesity-related chronic diseases get healthier. But it sells its services to health insurers and big employers, who benefit when their enrollees or employees make healthier choices.
About 20,000 patients use its platform currently, a number that's expected to jump by an additional 10,000 by year-end, Duffy told me this week. But by next year, he projects that "hundreds of thousands" of individuals will be using Omada Health to deal with chronic conditions like obesity and diabetes, in many cases before they reach the "tipping point" where they topple into experiencing the full-fledged medical condition.
Read More: http://www.bizjournals.com/sanjose/blog/techflash/2015/09/omada-sean-duffy-digital-health.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_sanjose+%28Silicon+Valley+%2F+San+Jose+Business+Journal%29
OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference
NEW YORK and REDWOOD CITY, Calif., Sept. 16, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today presented preclinical data for the company's proprietary, wholly owned GITRL-Fc agent during the afternoon poster session of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference.
Omada Health, which provides a digital program based on the landmark NIH diabetes prevention study, raised $48 million, bringing total funding to $77.5 million. The series C round was led by Norwest Venture Partners, and includes returning investors Andreessen Horowitz and US Venture Partners, among others. Accelerator-turned venture fund Rock Health which nurtured Omada in its first class of digital health startups, also reinvested.
OncoMed Pharmaceuticals Completes Enrollment of Phase 2 ALPINE Clinical Trial of Tarextumab in Pancreatic Cancer
Enrollment of 177 Patients Completed Over Eight Months Ahead of Schedule
REDWOOD CITY, Calif., July 28, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its anti-RSPO3 antibody (OMP-131R10) Phase 1a/1b clinical trial. Anti-RSPO3 is the first drug in its class to target the R-spondin-LGR pathway, an important cancer stem cell pathway identified by OncoMed researchers.
We caught up with leading founders in digital health to tap their insider expertise on everything you need to know about building a company in healthcare—from recruiting top talent and building a company on human-centered design principles to hospital sales and putting your customers first. Here are the four newest installments in our Startup Elements series:
Sean Duffy, cofounder and CEO of Rock Health portfolio company Omada Health discusses how the company shapes their internal and external practices around human-centered design principles.
Via: Mass Device
Outset Medical, previously Home Dialysis Plus, said it raised $91 million in a new funding round, with $51 million in equity and $40 million in debt funding. Funds are slated to continue development and promotion of its Tablo all-in-one dialysis system.
Dialysis player Outset Medical attracted a lot of media attention last month when it released an SEC filing for a $60 million equity financing. Now, it's ready to give a much more detailed account of the financing and the plans for its Tablo product, which it touts as the first consumer-friendly, all-in-one dialysis device to get through the FDA.
OncoMed and Lilly Enter Clinical Supply Agreement to Evaluate the Combination of Demcizumab and Alimta(R) (pemetrexed for injection) in Lung Cancer
REDWOOD CITY, Calif., April 2, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, announced today that it has entered into an agreement with Eli Lilly and Company. Demcizumab, OncoMed's anti-DLL4 antibody, is being tested in combination with Lilly's Alimta® (pemetrexed for injection) and carboplatin for the treatment of first-line advanced non-small cell lung cancer (NSCLC). Under the terms of this agreement, Lilly will provide clinical supply of Alimta for OncoMed's ongoing Phase 2 DENALI trial.
OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting
REDWOOD CITY, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology candidates in a total of seven presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 18-22, 2015 in Philadelphia, PA.